Way Towards New Life

Multiple Myeloma Medications

Alleviare promptly facilitates Indian patients and physicians under Named Patient Programs (NPP) to access imported authorized medicines that are not locally available to them.

Get access to an Multiple Myeloma - Anticancer medicine (unapproved drug in India) for personal use.

Here is a list of some of the  Drugs for Multiple Myeloma Medications for which we currently have a NPP in place. If you are a patient or  healthcare professional, please click below on each to access details and information.

ALKERAN (melphalan) Tablets

Indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma

EMPLICITI (elotuzumab) for injection

Indicated for the treatment of multiple myeloma in combination with the medicines: REVLIMID® (lenalidomide) and dexamethasone in adults

KYPROLIS (carfilzomib) for Injection

Indicated for the treatment of multiple myeloma (a cancer of the bone marrow)

NINLARO (ixazomib) capsules

Indicated for the treatment of multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone, in people

TALVEY (talquetamab-tgvs) injection

TALVEY is a bispecific antibody, or a type of medicine that targets 2 different proteins in the body. Indicated for the treatment of multiple myeloma.

SARCLISA (isatuximab-irfc) injection

Indicated for the treatment of multiple myeloma

FARYDAK (panobinostat) capsules

Indicated for the treatment of multiple myeloma, which is a type of cancer that affects plasma cells.

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Query Form

We would love to speak with you.
Feel free to reach out using the below details.

Access Unauthorized Medicines In India Under NPP.

What is Named-patient access programme (NPP)?

Named-patient basis access can also refer to a medicine for a specific patient or patients that is not (yet) authorised and available to them in their own country. Such medicine should or must (depending on legislation) be authorised in at least one country, from which it can be imported into the patient’s country under a Named-patient access programme (NPP).

These may be medicines that are:

  • Authorised but not yet available to be prescribed in the patient’s country.
  • Authorised and available in one country but not authorised and available in the patient’s country.
  • Discontinued in the patient’s country but not in another country.
  • In shortage in the patient’s country but not in another country.

Antibiotic

Arthritis

Diabetes

Genetics

Disorders

Hepatitis C

Hematologic Cancers

HIV/AIDS

Immunological Disorders

Liver Disease

Multiple Sclerosis

Nerver Disease

Oncology

Parkinson's Disease

Rare Disease

Soft Tissue Sarcoma

Transplant

Specialty Drugs

Get access to an imported medicines (unapproved drug in India) for Multiple Myeloma.

For personal use, get access to an imported medicines (unapproved drug in India) for Blood Disorders – Multiple Myeloma. On request, Anti-cancer medicines can be imported to following cities in India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Alleviare provides only information & in any way, does not lay any claim on these brand names &/or trademarks.